OB/GYN and Women's Health

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP In addition to heavy menstrual bleeding, patients with uterine fibroids often deal with many other considerable effects on their physical and mental wellbeing. To provide optimal care, it’s important to recognize the full impact of fibroids, communicate carefully about treatment options, and promote equitable access to care. Dr. Charles Turck sits down with Dr. Ayman Al-Hendy to learn more about how we can address the multifaceted burden of uterine fibroids. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Joseph E. Patruno, MD From delayed diagnosis to chronic pain and fertility issues, endometriosis presents a range of challenges that require individualized attention. By focusing on each patient’s unique symptoms and priorities, we can better tailor care and improve outcomes. Join Dr. Mary Katherine Cheeley as she speaks with Dr. Joseph Patruno, an OB/GYN at Lehigh Valley Jefferson Health Network, about practical strategies for delivering comprehensive, patient-centered care.

Guest: Riley Bove, MD, MMSc From pregnancy planning and postpartum relapse risk to the overlapping symptoms of menopause, women with multiple sclerosis (MS) face unique challenges throughout the reproductive lifespan. Here to share key takeaways from her session at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting that focused on how we can better care for these patients is Dr. Riley Bove, a practicing neurologist and clinician scientist in the UCSF Weill Institute for Neurosciences.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Despite longstanding reliance on surgery, recent advancements have reshaped our approach to uterine fibroids. However, common myths and misconceptions have limited the adoption of newer therapies, leaving many patients unaware of their available options. Join Dr. Charles Turck and Dr. Ayman Al-Hendy as they explain shifting treatment paradigms and patient education strategies in uterine fibroid care. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Guest: Megan Kruse, MD When treating patients with metastatic breast cancer, effective communication and patient support are key. Join Dr. Megan Kruse, a medical oncologist at Cleveland Clinic in Ohio, as she explains how to align treatment goals with patient values, address physical and emotional needs through multidisciplinary support, and incorporate integrative medicine approaches.

Host: Megan Kruse, MD When treating patients with HER2-positive metastatic breast cancer, understanding how to monitor and manage potential side effects is essential for optimal care. Join Dr. Megan Kruse, a medical oncologist at Cleveland Clinic in Ohio, as she explains key considerations for managing side effects from tucatinib and trastuzumab deruxtecan.

Guest: Fernando López-Ríos, MD, PhD Guest: Christian Rolfo, MD, PhD Guest: Prof. Charlie Gourley In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers. Topics of conversation include the following: Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer. The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it’s still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Host: Claire Gill Guest: Andrea Singer, MD, FACP, CCD Menopause accelerates bone loss due to declining estrogen levels, increasing the risk of osteoporosis and fractures. To learn how we can best support bone health during this transition, CEO of the Bone Health and Osteoporosis Foundation Claire Gill speaks with Dr. Andrea Singer, Chief Medical Officer of the Bone Health and Osteoporosis Foundation, Professor of Medicine and Obstetrics and Gynecology at MedStar Georgetown University Hospital, and a member of the National Menopause Foundation's Medical Advisory Committee.

Host: Brian Slomovitz, MD Guest: Robert L. Coleman, MD, FACOG, FACS In recent years, the treatment landscape for recurrent or metastatic cervical cancer has undergone significant shifts with FDA approvals of first-line pembrolizumab plus platinum-doublet with or without bevacizumab and second-line tisotumab vedotin. The introduction of frontline immune checkpoint blockade also added to the challenges faced by clinicians as they choose optimal regimens for their patients. In this online CME activity, Dr. Coleman and Dr. Slomovitz offer strategies for treatment selection and sequencing with immune checkpoint inhibitors and antibody-drug conjugates for relapsed cervical cancer. Tune in to hear their expert perspectives on biomarker testing, clinical trial evidence, and multidisciplinary management of adverse events associated with these therapies to make sure your patients are getting the most out of these advances.